Literature DB >> 21239697

Functional study of the vitamin K cycle in mammalian cells.

Jian-Ke Tie1, Da-Yun Jin, David L Straight, Darrel W Stafford.   

Abstract

We describe a cell-based assay for studying vitamin K-cycle enzymes. A reporter protein consisting of the gla domain of factor IX (amino acids 1-46) and residues 47-420 of protein C was stably expressed in HEK293 and AV12 cells. Both cell lines secrete carboxylated reporter when fed vitamin K or vitamin K epoxide (KO). However, neither cell line carboxylated the reporter when fed KO in the presence of warfarin. In the presence of warfarin, vitamin K rescued carboxylation in HEK293 cells but not in AV12 cells. Dicoumarol, an NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) inhibitor, behaved similarly to warfarin in both cell lines. Warfarin-resistant vitamin K epoxide reductase (VKOR-Y139F) supported carboxylation in HEK293 cells when fed KO in the presence of warfarin, but it did not in AV12 cells. These results suggest the following: (1) our cell system is a good model for studying the vitamin K cycle, (2) the warfarin-resistant enzyme reducing vitamin K to hydroquinone (KH₂) is probably not NQO1, (3) there appears to be a warfarin-sensitive enzyme other than VKOR that reduces vitamin K to KH₂, and (4) the primary function of VKOR is the reduction of KO to vitamin K.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239697      PMCID: PMC3062303          DOI: 10.1182/blood-2010-08-304303

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects.

Authors:  Leon J Schurgers; Martin J Shearer; Karly Hamulyák; Elisabeth Stöcklin; Cees Vermeer
Journal:  Blood       Date:  2004-07-01       Impact factor: 22.113

2.  The enzymatic reduction of K-vitamins incorporated in the membrane of liposomes.

Authors:  C Martius; R Ganser; A Viviani
Journal:  FEBS Lett       Date:  1975-11-01       Impact factor: 4.124

3.  Vitamin K antagonism of coumarin anticoagulation. A dehydrogenase pathway in rat liver is responsible for the antagonistic effect.

Authors:  R Wallin
Journal:  Biochem J       Date:  1986-06-15       Impact factor: 3.857

4.  Vitamin K1 disposition and therapy of warfarin overdose.

Authors:  T D Bjornsson; T F Blaschke
Journal:  Lancet       Date:  1978-10-14       Impact factor: 79.321

5.  Vitamin K1 and therapy of massive warfarin overdose.

Authors:  M J Shearer; P Barkhan
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

6.  Vitamin K1 hydroquinone formation catalyzed by DT-diaphorase.

Authors:  M J Fasco; L M Principe
Journal:  Biochem Biophys Res Commun       Date:  1982-01-15       Impact factor: 3.575

7.  Vitamin K epoxide reductase: evidence that vitamin K dihydroquinone is a product of vitamin K epoxide reduction.

Authors:  P A Sherman; E G Sander
Journal:  Biochem Biophys Res Commun       Date:  1981-12-15       Impact factor: 3.575

8.  Vitamin K1 hydroquinone formation catalyzed by a microsomal reductase system.

Authors:  M J Fasco; L M Principe
Journal:  Biochem Biophys Res Commun       Date:  1980-12-31       Impact factor: 3.575

9.  Vitamin K-dependent carboxylation. Evidence that at least two microsomal dehydrogenases reduce vitamin K1 to support carboxylation.

Authors:  R Wallin; S Hutson
Journal:  J Biol Chem       Date:  1982-02-25       Impact factor: 5.157

10.  Vitamin K counteracts the effect of warfarin in liver but not in bone.

Authors:  P A Price; Y Kaneda
Journal:  Thromb Res       Date:  1987-04-01       Impact factor: 3.944

View more
  42 in total

1.  Mycobacterium tuberculosis vitamin K epoxide reductase homologue supports vitamin K-dependent carboxylation in mammalian cells.

Authors:  Jian-Ke Tie; Da-Yun Jin; Darrel W Stafford
Journal:  Antioxid Redox Signal       Date:  2011-11-22       Impact factor: 8.401

2.  Warfarin, a juggler's demise.

Authors:  Laurent O Mosnier
Journal:  Blood       Date:  2018-06-21       Impact factor: 22.113

3.  Characterization of vitamin K-dependent carboxylase mutations that cause bleeding and nonbleeding disorders.

Authors:  Jian-Ke Tie; Jorge D A Carneiro; Da-Yun Jin; Ciro D Martinhago; Cees Vermeer; Darrel W Stafford
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

4.  Functional Study of the Vitamin K Cycle Enzymes in Live Cells.

Authors:  J-K Tie; D W Stafford
Journal:  Methods Enzymol       Date:  2016-11-22       Impact factor: 1.600

5.  Insights into vitamin K-dependent carboxylation: home field advantage.

Authors:  Francis Ayombil; Rodney M Camire
Journal:  Haematologica       Date:  2020-08       Impact factor: 9.941

6.  Characterization of Warfarin Inhibition Kinetics Requires Stabilization of Intramembrane Vitamin K Epoxide Reductases.

Authors:  Shuang Li; Shixuan Liu; Yihu Yang; Weikai Li
Journal:  J Mol Biol       Date:  2020-05-20       Impact factor: 5.469

7.  Warfarin alters vitamin K metabolism: a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase.

Authors:  Mark A Rishavy; Kevin W Hallgren; Lee Wilson; Savita Singh; Kurt W Runge; Kathleen L Berkner
Journal:  Blood       Date:  2018-03-28       Impact factor: 22.113

8.  Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.

Authors:  J-K Tie; D-Y Jin; K Tie; D W Stafford
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

9.  A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.

Authors:  Jamil A Haque; Matthew G McDonald; John D Kulman; Allan E Rettie
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

10.  Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.

Authors:  Jee-Eun Chung; Byung Chul Chang; Kyung Eun Lee; Joo Hee Kim; Hye Sun Gwak
Journal:  Eur J Clin Pharmacol       Date:  2015-08-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.